Rocket Lab has formally pushed the maiden launch of its reusable medium-lift Neutron rocket into 2027, abandoning the fourth-quarter 2026 target it had been guiding toward. The Long Beach-based space company disclosed the revised schedule in a mandatory 8-K filing with the U.S. Securities and Exchange Commission on Wednesday, a move that landed hard on a stock already nursing a deep retreat from its highs.
The shares gave up 7.5% during Wednesday’s session to close at EUR 53.10, with Reuters reporting that the announcement had already weighed on the stock in after-hours trading the night before. Thursday brought no relief: the equity was down another 8.0% in premarket action at EUR 48.85. The selloff leaves Rocket Lab trading roughly 60% below its 52-week peak.
A Manufacturing Defect, Not a Design Failure
At the root of the slip are voids discovered in the carbon-fiber composite dome that caps the forward fuel tank of the first stage. CEO Peter Beck characterized the flaw as understood and corrected, but acknowledged that the remediation itself carries an unavoidable cost in time. The question now narrowing for investors is whether Rocket Lab can complete the reworked manufacturing process without encountering further material defects.
The problem traces back to January 2026, when a prototype burst during a hydrostatic pressure test. Rocket Lab responded by switching production to an automated fiber placement process. The path forward requires building a replacement dome, verifying it by ultrasound, and integrating it into the first stage. Only after successful pressure and cryogenic testing in the first quarter does management intend to commit to a precise launch date.
Core Operations and a Fat Balance Sheet Buy Time
What separates Rocket Lab from pure development-stage ventures is a revenue-generating business underneath the Neutron program. Alongside its workhorse Electron rocket, the company conducts suborbital HASTE missions, and its components and satellites have featured in more than 1,700 missions, according to company figures. Management also inked a deal for 20 additional missions with Synspective just last month.
The cash position gives the team room to absorb setbacks. As of the end of June 2026, Rocket Lab held roughly USD 2.4 billion in liquid funds and marketable securities. For the third quarter of 2026, management guided toward an adjusted EBITDA loss of between USD 17 million and USD 23 million.
Should investors sell immediately? Or is it worth buying Rocket Lab?
Progress on propulsion is tangible as well: the company reported more than 400 hot-fire tests of its Archimedes engines for the first and second stages as of August. Should the debut flight come off in 2027, the strategic expansion thesis stays fundamentally intact.
Three Years Behind the Original Promise
Even so, the latest postponement tightens the squeeze on profitability targets. When Neutron was first unveiled in March 2021, the official first-flight goal was 2024. Through interim waypoints in 2025 and late 2026, the timeline now trails the original announcement by three years. Every lost quarter drags the projected financial inflection point along with it.
Rocket Lab has said it expects to cross into positive adjusted EBITDA in the quarter following a successful first flight, with free cash flow breakeven arriving roughly 18 to 24 months after that. The stakes of the coming tests are therefore high. Should the first-quarter trials expose fresh weaknesses, the company faces not only potential additional capital needs but also rework across its entire production chain, since the second and third rockets are already under construction at the Wallops Island launch complex.
Wall Street Stays Constructive, With Caveats
Despite the schedule hit, sell-side analysts remain largely supportive of the fundamental story. Barclays initiated coverage on October 8 with an Overweight rating and an USD 85 price target, while Goldman Sachs maintains a neutral stance with a USD 75 target, trimmed from USD 80.
The market’s sharp reaction underscores how sensitive investors have become to delays in flagship development programs. For now, the swift resolution of the first-stage manufacturing defects is the single factor that will determine whether the 2027 launch window holds. The decisive milestone arrives in the first quarter: only once the first stage clears its pressure and cryogenic load tests will Rocket Lab set a definitive date for the Neutron’s debut.
Ad
Rocket Lab Stock: Buy or Sell?! New Rocket Lab Analysis from October 15 delivers the answer:
The latest Rocket Lab figures speak for themselves: Urgent action needed for Rocket Lab investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from October 15.
Rocket Lab: Buy or sell? Read more here...
